Patents Assigned to Omrix Biopharmaceuticals Inc.
-
Patent number: 9439997Abstract: The present invention is directed to a reinforced absorbable multilayered hemostatic wound dressing comprising a first absorbable nonwoven fabric, a second absorbable woven or knitted fabric, thrombin and/or fibrinogen.Type: GrantFiled: April 10, 2006Date of Patent: September 13, 2016Assignees: Ethicon, Inc., Omrix Biopharmaceutical, Inc.Inventors: Anne Jessica Gorman, Sanyog Manohar Pendharkar, Guanghui Zhang, Liliana Bar, Israel Nur, Roberto Meidler
-
Patent number: 9358318Abstract: The present invention is directed to a reinforced absorbable multilayered hemostatic wound dressing comprising a first absorbable nonwoven fabric, a second absorbable woven or knitted fabric, thrombin and/or fibrinogen.Type: GrantFiled: March 9, 2009Date of Patent: June 7, 2016Assignees: Ethicon, Inc., Omrix Biopharmaceutical, Inc.Inventors: Anne Jessica Gorman, Sanyog Manohar Pendharkar
-
Patent number: 8563288Abstract: A method for specifically removing or isolating plasmin(ogen) or plasmin in presence of fibrinogen from a mixture containing plasmin(ogen) or plasmin by contacting the mixture with a rigid amino acid wherein the amino group of the amino acid and the carboxylic group of the amino acid are about 6-8 Angstroms, preferably about 7 Angstroms apart and the rigid amino acid is covalently bound to the support via the amino group of the amino acid.Type: GrantFiled: October 29, 2008Date of Patent: October 22, 2013Assignee: Omrix Biopharmaceuticals Inc.Inventors: Israel Nur, Liliana Bar, Malkit Azachi
-
Publication number: 20130244925Abstract: Specific peptides have been discovered that mimic an idiotype of an autoantibody. Such peptides may be formed into polymers. The peptides may be used in pharmaceutical compositions for the treatment of an autoimmune disease together with a pharmaceutically acceptable excipient.Type: ApplicationFiled: May 26, 2013Publication date: September 19, 2013Applicant: Omrix Biopharmaceuticals Inc.Inventors: Israel NUR, Yehuda SHOENFELD, Miri BLANK
-
Patent number: 8450067Abstract: A method for identifying molecules which mimic an idiotype of an autoimmune disease-associated auto-antibody (autoantibodies). The method comprises the following steps: (a) purifying autoantibodies from sera of one or more patients afflicted with the autoimmune disease; (b) binding the autoantibodies to a solid phase to form an affinity matrix; (c) contacting pooled plasma or B cells comprising immunoglobulins with the affinity matrix followed by removal of unbound plasma components; (d) eluting bound immunoglobulins, being anti-Idiotypic antibodies (anti-Id) to autoantibodies, from the matrix; (e) providing a molecular library comprising a plurality of molecule members; and (e) contacting the anti-Id with the molecular library and isolating those bound molecules which are bound by the anti-Id, the bound molecules being molecules which mimic an idiotype of autoantibodies. Also disclosed are such molecules.Type: GrantFiled: May 22, 2003Date of Patent: May 28, 2013Assignee: Omrix Biopharmaceuticals Inc.Inventors: Israel Nur, Yehuda Shoenfeld, Miri Blank
-
Patent number: 7641918Abstract: A method for specifically removing or isolating plasmin(ogen) or plasmin in presence of fibrinogen from a mixture containing plasmin(ogen) or plasmin by contacting the mixture with a rigid amino acid wherein the amino group of the amino acid and the carboxylic group of the amino acid are about 6-8 Angstroms, preferably about 7 Angstroms apart and the rigid amino acid is covalently bound to the support via the amino group of the amino acid.Type: GrantFiled: October 17, 2006Date of Patent: January 5, 2010Assignee: Omrix Biopharmaceuticals Inc.Inventors: Israel Nur, Liliana Bar, Malkit Azachi
-
Patent number: 7125569Abstract: A method for specifically removing or isolating plasmin(ogen) or plasmin in presence of fibrinogen from a mixture containing plasmin(ogen) or plasmin by contacting the mixture with a rigid amino acid wherein the amino group of the amino acid and the carboxylic group of the amino acid are about 6–8 Angstroms, preferably about 7 Angstroms apart and the rigid amino acid is covalently bound to the support via the amino group of the amino acid.Type: GrantFiled: May 20, 2002Date of Patent: October 24, 2006Assignee: Omrix Biopharmaceuticals Inc.Inventors: Israel Nur, Liliana Bar, Malkit Azachi
-
Publication number: 20060078943Abstract: A method for identifying molecules which mimic an idiotype of an autoimmune disease-associated auto-antibody (autoantibodies). The method comprises the following steps: (a) purifying autoantibodies from sera of one or more patients afflicted with the autoimmune disease; (b) binding the autoantibodies to a solid phase to form an affinity matrix; (c) contacting pooled plasma or B cells comprising immunoglobulins with the affinity matrix followed by removal of unbound plasma components; (d) eluting bound immunoglobulins, being anti-Idiotypic antibodies (anti-Id) to autoantibodies, from the matrix; (e) providing a molecular library comprising a plurality of molecule members; and (e) contacting the anti-Id with the molecular library and isolating those bound molecules which are bound by the anti-Id, the bound molecules being molecules which mimic an idiotype of autoantibodies. Also disclosed are such molecules.Type: ApplicationFiled: May 22, 2003Publication date: April 13, 2006Applicant: Omrix Biopharmaceuticals Inc.Inventors: Israel Nur, Yehuda Shoenfeld
-
Patent number: 6468733Abstract: The invention concerns a method for elimination of viruses from a biological preparation wherein initially enveloped viruses are eliminated by a solvent-detergent step, then the solvent-detergents are removed by a resin composed of silicon beads and finally the preparation is nanofiltered.Type: GrantFiled: April 27, 2001Date of Patent: October 22, 2002Assignee: Omrix Biopharmaceuticals Inc.Inventors: Israel Nur, Liliana Bar